REGULATORY PRESS RELEASE

Magnasense AB held its annual general meeting on 30 June 2025, whereby essentially the following resolutions were made.

Income statements and balance sheets
The meeting resolved to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2024.

Allocation of the company’s profit and loss
The meeting resolved, in accordance with the proposal of the board of directors, that no dividend shall be paid for the financial year 2024 and that the company’s funds at its disposal shall be carried forward.

Discharge from liability
The meeting resolved to grant discharge from liability to all persons who have had the position of board member or CEO in the company during 2024.

Remuneration of the board of directors and auditor
The meeting resolved, in accordance with the proposal of a group of shareholders, that the remuneration of the board of directors, per member elected by the meeting who is not employed by the company, shall be paid as follows: three (3) price base amounts to the chairman of the board of directors and two (2) price base amounts to an ordinary member.

The meeting resolved, in accordance with the proposal of a group of shareholders, that the renumeration to the company’s auditor shall be paid according to approved invoices.

Election of the board of directors and auditor
The meeting resolved, in accordance with the proposal of a group of shareholders, that the board of directors shall consist of six (6) ordinary members with no deputies and that a registered auditing firm shall be appointed as auditor.

The meeting resolved, in accordance with the proposal of a group of shareholders, to re-elect Jens Umehag, Michael Schwartz, William Ferenczy, Fredrik Häglund, William Vickery and Marco Witteveen. Jens Umehag was re-elected as chairman of the board of directors, in accordance with the proposal of a group of shareholders.

The meeting resolved, in accordance with the board’s proposal, to elect the registered auditing firm Göteborgs Revision KB as auditor for the period until the end of the next annual general meeting. Göteborgs Revision KB has announced that the authorised public accountant Stefan Kylebäck will be the auditor in charge.

Resolution to amend the Articles of Association
The meeting resolved, in accordance with the proposal of the board of directors, to amend article 4 of the articles of association to amend the limits of the share capital and number of shares.

Resolution on amendment of terms for convertible bonds of series 2023/2026
The meeting resolved, in accordance with the board’s proposal, to amend the terms of the company's convertible bonds of series 2023/2026. The main changes to the terms mean that the maturity date of the loan is changed to 20 January 2028 and that conversion can be requested up to and including 2 January 2028.

Authorisation for the board of directors to resolve on a share issue etc.
The meeting resolved, in accordance with the board’s proposal, to authorise the board of directors, for the period until the next annual general meeting, on one or more occasions, to resolve to increase the company’s share capital by issuing new shares, warrants and/or convertible bonds. The issue may be made with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, or set-off, in addition to cash payment. The purpose of the authorisation is to secure the company’s obligations under the agreement with Atlas Special Opportunities, LLC.

Authorisation for the board of directors to resolve on a share issue etc.
The meeting resolved, in accordance with the board’s proposal, to authorise the board of directors, for the period until the next annual general meeting, on one or more occasions, with or without pre-emption rights for the shareholders, to adopt resolutions to issue new shares, warrants and/or convertible debentures. Such new issue resolutions may include provisions of payment in cash and/or payment by way of contribution of non-cash consideration or by set-off of a claim or that subscription shall be subject to other conditions. The company's share capital and number of shares may, by virtue of the authorisation, be increased by an amount and number that does not exceed the limits set out in the articles of association in force at any given time or as adopted by the general meeting.

The reason for the board of directors’ authorisation to deviate from the shareholders’ preferential rights is to enable the company to raise new capital, and/or strengthen the Company’s financial position and/or to take advantage of future opportunities to attract new long-term owners. At a deviation from the shareholders’ preferential rights, the issue rate shall be determined in accordance with market conditions, taking into account any discount on market terms.

__________

For further information, please contact:
Marco Witteveen, CEO, Magnasense AB
E-mail: ir@magnasense.com
The Company's Certified Adviser is Eminova Fondkomission AB | adviser@eminova.se

About Magnasense

Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.